Patents by Inventor Andre Mann
Andre Mann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230161024Abstract: The present invention relates to an apparatus for determining the position of objects in two-dimensional space having a first dimension and a second dimension, the direction vector of which is orthogonal to the direction vector of the first dimension, containing at least one transmitter (I) having at least one transmitting antenna (3) and an imaging receiver circuit (2) having at least one receiving antenna array (Rx Array) with rows (6) of receiving antennas for scanning the first dimension by means of digital beam shaping, wherein the receiving antenna array has a linear array, a sparse array or an array with an enlarged aperture, and wherein the rows (6) of receiving antennas in the receiving antenna array of the receiver circuit (2) are linearly arranged in the first dimension according to a curve function or according to the contour of a two-dimensional geometric object and are spread out in the second dimension, and to a method using the apparatus.Type: ApplicationFiled: January 16, 2023Publication date: May 25, 2023Inventors: Andre Giere, Johanna Guetlein-Holzer, Sebastian Mann
-
Patent number: 9303019Abstract: Novel amino-pyrrolinic derivatives, their pharmacologically acceptable salts and use thereof in the prevention and/or treatment of metabolic syndrome.Type: GrantFiled: April 17, 2012Date of Patent: April 5, 2016Assignee: UNIVERSITE DE STRASBOURGInventors: Pascal Bousquet, Jean Daniel Ehrhardt, Lyne Fellmann, Vincent Gasparik, Hugues Greney, Mohamed Hadjeri, Andre Mann, Nathalie Niederhoffer, Stephan Schann
-
Patent number: 9073835Abstract: The present invention relates to the use of acylthiourea or acylurea derivatives for the treatment of pathologies involving a tissue dysfunction associated with a deregulation of the Hedgehog protein signalling pathway, and also to novel acylthiourea or acylurea derivatives as such, to their use as a medicinal product, and to pharmaceutical compositions containing them.Type: GrantFiled: April 16, 2009Date of Patent: July 7, 2015Assignees: Centre National De La Recherche Scientifique, Universite De StrasbourgInventors: Martial Ruat, Hélène Faure, Elisabeth Traiffort, Angèle Schoenfelder, André Mann, Maurizio Taddei, Antonio Solinas, Fabrizio Manetti
-
Patent number: 9061997Abstract: The present invention relates to compounds which are quinolinone derivatives of general formula (I) capable of modulating the activity, in particular of inducing the differentiation, of stem and progenitor cells; these compounds are of use in the treatment of disorders related to a stem differentiation defect; the invention also relates to novel compounds among these quinolinone derivatives and to pharmaceutical compositions containing the same.Type: GrantFiled: November 15, 2011Date of Patent: June 23, 2015Assignee: Centre National de la Recherche ScientifiqueInventors: Martial Ruat, Hélène Faure, Tatiana Gorojankina, André Mann, Maurizio Taddei, Fabrizio Manetti, Antonio Solinas
-
Patent number: 8981149Abstract: The invention relates to compounds of formula (I), and the use thereof as a drug, particularly for the treatment of tumors associated with hyperactivation of the hedgehog protein signaling pathway, treatment of neurodegenerative diseases, treatment of diseases related to cerebral development (holoprosencephaly), for stem cell monitoring treatment of cerebrovascular accidents and cardiovascular accidents, treatment of diseases involving oligodendrocytes and diseases involving neurolemmocytes, for application thereof in vitro for modulating human or animal stem cell renewal, and for the treatment of diabetes. The invention also relates to pharmaceutical compositions having a compound of formula (I).Type: GrantFiled: September 21, 2012Date of Patent: March 17, 2015Assignees: Centre National de la Recherche Scientifique, Universite de StrasbourgInventors: Martial Ruat, Hélène Faure, Hermine Roudaut, Lucile Hoch, Angèle Schoenfelder, Maurizio Taddei, André Mann
-
Patent number: 8889678Abstract: The present invention relates to acyl guanidine derivatives modulating the hedgehog protein signaling pathway to be used as drugs, in particular for treating diseases involving a tissue dysfunction associated with a deregulation of the hedgehog protein signaling pathway, as well as to pharmaceutical compositions containing same. The present invention also relates to novel acyl guanidine derivatives as such.Type: GrantFiled: July 19, 2010Date of Patent: November 18, 2014Assignees: Centre National de la Recherche Scientifique, Universite de StrasbourgInventors: Martial Ruat, Hélène Faure, Elisabeth Traiffort, Hermine Roudaut, André Mann, Angèle Schoenfelder, Maurizio Taddei, Fabrizio Manetti, Antonio Solinas
-
Publication number: 20140228441Abstract: The invention relates to compounds of formula (I), and the use thereof as a drug, particularly for the treatment of tumors associated with hyperactivation of the hedgehog protein signaling pathway, treatment of neurodegenerative diseases, treatment of diseases related to cerebral development (holoprosencephaly), for stem cell monitoring treatment of cerebrovascular accidents and cardiovascular accidents, treatment of diseases involving oligodendrocytes and diseases involving neurolemmocytes, for application thereof in vitro for modulating human or animal stem cell renewal, and for the treatment of diabetes. The invention also relates to pharmaceutical compositions having a compound of formula (I).Type: ApplicationFiled: September 21, 2012Publication date: August 14, 2014Applicants: Centre National De La Recherche Scientifique, Universite De StrasbourgInventors: Martial Ruat, Hélène Faure, Hermine Roudaut, Lucile Hoch, Angèle Schoenfelder, Maurizio Taddei, André Mann
-
Publication number: 20140045910Abstract: Novel amino-pyrrolinic derivatives, their pharmacologically acceptable salts and use thereof in the prevention and/or treatment of metabolic syndrome.Type: ApplicationFiled: April 17, 2012Publication date: February 13, 2014Applicant: UNIVERSITE DE STRASBOURGInventors: Pascal Bousquet, Jean Daniel Ehrhardt, Lyne Fellmann, Vincent Gasparik, Hugues Greney, Mohamed Hadjeri, Andre Mann, Nathalie Niederhoffer, Stephan Schann
-
Publication number: 20130267559Abstract: The present invention relates to compounds which are quinolinone derivatives of general formula (I) capable of modulating the activity, in particular of inducing the differentiation, of stem and progenitor cells; these compounds are of use in the treatment of disorders related to a stem differentiation defect; the invention also relates to novel compounds among these quinolinone derivatives and to pharmaceutical compositions containing the same.Type: ApplicationFiled: November 15, 2011Publication date: October 10, 2013Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Martial Ruat, Helene Faure, Tatiana Gorojankina, Andre Mann, Maurizio Taddei, Fabrizio Manetti, Antonio Solinas
-
Publication number: 20120196865Abstract: The present invention relates to acyl guanidine derivatives modulating the hedgehog protein signaling pathway to be used as drugs, in particular for treating diseases involving a tissue dysfunction associated with a deregulation of the hedgehog protein signaling pathway, as well as to pharmaceutical compositions containing same. The present invention also relates to novel acyl guanidine derivatives as such.Type: ApplicationFiled: July 19, 2010Publication date: August 2, 2012Applicants: UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Martial Ruat, Hélène Faure, Elisabeth Traiffort, Hermine Roudaut, André Mann, Angèle Schoenfelder, Maurizio Taddei, Fabrizio Manetti, Antonio Solinas
-
Publication number: 20110275663Abstract: The present invention relates to the use of acylthiourea or acylurea derivatives for the treatment of pathologies involving a tissue dysfunction associated with a deregulation of the Hedgehog protein signalling pathway, and also to novel acylthiourea or acylurea derivatives as such, to their use as a medicinal product, and to pharmaceutical compositions containing them.Type: ApplicationFiled: April 16, 2009Publication date: November 10, 2011Inventors: Martial Ruat, Hélène Faure, Elisabeth Traiffort, Angèle Schoenfelder, André Mann, Maurizio Taddei, Antonio Solinas, Fabrizio Manetti
-
Patent number: 7875617Abstract: The invention relates to 3,4-dihydro-2-naphthamide derivatives of formula (I), pharmaceutical compositions containing them and their therapeutic applications as partial agonists or antagonists of the dopamine D3 receptor for the treatment of neuropsychological disorders.Type: GrantFiled: January 20, 2006Date of Patent: January 25, 2011Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Pierre Sokoloff, Catherine Pilon, André Mann, Angéle Schoenfelder, Fabrice Garrido
-
Publication number: 20090124630Abstract: The invention relates to 3,4-dihydro-2-naphthamide derivatives of formula (I), pharmaceutical compositions containing them and their therapeutic applications as partial agonists or antagonists of the dopamine D3 receptor for the treatment of neuropsychological disorders.Type: ApplicationFiled: January 20, 2006Publication date: May 14, 2009Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Pierre Sokoloff, Catherine Pilon, Andre Mann, Angele Schoenfelder, Fabrice Garrido
-
Publication number: 20070256307Abstract: A cutter designed to release and remove objects such as medication pills and the like from an encapsulated packaging such as a blister pack. The cutter includes at least one blade which is advanced proximate the bottom region of the object and which cuts through the packaging and releases the object. In the preferred embodiment, the cutter included two blades each coupled to a shaft. The two shafts are connected together proximate an end opposite the cutter end and pivot to allow one handed operation.Type: ApplicationFiled: May 4, 2007Publication date: November 8, 2007Inventor: Andre Mann
-
Patent number: 5985895Abstract: The invention relates to 2-naphthamide derivatives, in the form of bases or of salts, corresponding to the following general formula (I): ##STR1## in which: the Z-Y entity represents an N--CH.sub.2, C.dbd.CH or CH--CH.sub.2 group;R.sup.1 represents a hydrogen, fluorine, bromine or iodine atom or a hydroxyl, methoxy, nitrile or nitro group;R.sup.2 represents a hydrogen or bromine atom or a hydroxyl, methoxy, nitrile or nitro group;the R.sub.1 and R.sub.2 substituents both being situated on the same ring of the naphthamide unit or each being situated on one of the rings;R.sup.3 and R.sup.4 can be identical or different and each independently represent a hydrogen or chlorine atom or a methoxy or methyl group or an electron-withdrawing group.The invention also relates to their therapeutic applications as partial agonists of the dopamine D.sub.3 receptor.The invention applies more particularly to the treatment of neuropsychiatric conditions involving the dopamine D.sub.Type: GrantFiled: June 26, 1998Date of Patent: November 16, 1999Assignees: Institut National De La Sante et De La Recherche Medicale-INSERM, Societe Civile BioprojetInventors: Camille-Georges Wermuth, Andre Mann, Fabrice Garrido, Jeanne-Marie Lecomte, Jean-Charles Schwartz, Pierre Sokoloff
-
Patent number: 5872119Abstract: The invention related to 2-naphthamide derivatives, in the form of bases or of salts, corresponding to the following general formula (I): ##STR1## in which: the Z--Y entity represents an N--CH.sub.2, C.dbd.CH or CH--CH.sub.2 group;R.sup.1 represents a hydrogen, fluorine, bromine or iodine atom or a hydroxyl, methoxy, nitrile or nitro group;R.sup.2 represents a hydrogen or bromine atom or a hydroxyl, methoxy, nitrile or nitro group;the R.sub.1 and R.sup.2 substituents both being situated on the same ring of the naphthamide unit or each being situated on one of the rings;R.sup.3 and R.sup.4 can be identical or different and each independently represent a hydrogen or chlorine atom or a methoxy or methyl group or an electron-withdrawing group.The invention also relates to their therapeutic applications as partial agonists of the dopamine D.sub.3 receptor.The invention applies more particularly to the treatment of neuropsychiatric conditions involving the dopamine D.sub.Type: GrantFiled: December 10, 1996Date of Patent: February 16, 1999Assignees: Institut National De La Sante et De La Recherche Medicale--INSERM, Societe Civile BrioprojetInventors: Camille-Georges Wermuth, Andre Mann, Fabrice Garrido, Jeanne-Marie Lecomte, Jean-Charles Schwartz, Pierre Sokoloff
-
Patent number: 5739164Abstract: Disclosed herein is a method of treating a disease of the central nervous system with a compound of the formula ##STR1## in which m is 0, 1 or 2, n and q are each 0 or 1 to 5, and p is 0 or 1, X is --CO.sub.2 H or tetrazolyl,Y is --CH.dbd.CH--, andZ is(i) phenyl, naphthyl or thienyl, said phenyl, naphthyl and thienyl being optionally substituted,(ii) --CHR.sup.1 R.sup.2 where R.sup.1 and R.sup.2 are each phenyl, naphthyl or thienyl, said phenyl, naphthyl and thienyl being optionally substituted,(iii) .dbd.CR.sup.1 R.sup.2 where R.sup.1 and R.sup.2 are each phenyl, naphthyl or thienyl, said phenyl, naphthyl and thienyl being optionally substituted, or(iv) ##STR2## where r is 0 or 1 to 3 and the phenyl rings are optionally substituted; provided that when Z is phenyl and m is 1, p is 1; and salts and esters thereof.Type: GrantFiled: September 13, 1996Date of Patent: April 14, 1998Assignee: Eli Lilly and CompanyInventors: Jesus Ezquerra Carrera, Almudena Rubio Esteban, Andre Mann, Angele Schoenfelder, Darryle Darwin Schoepp, Concepcion Pedregal Tercero, Camille-Georges Wermuth
-
Patent number: 5498628Abstract: The new naphthamide derivatives according to the invention are characterized in that they correspond to the general formula (I), ##STR1## where X: represents either a hydrogen atom, or a chlorine or bromine atom, or an amino or aminoalkyl group, an aminosulphamoyl group, a sulphur-containing group such as thiocyanate, alkylthio, alkylsulphinyl or alkylsulphonyl, or a methoxy group, or a nitro group, or a cyano group, or an electron-attracting group;Y: represents an alkyl or alkenyl residue;Z: represents the residues originating from 2-aminomethyl-N-alkylpyrrolidine, 2-aminoethyl-N,N-diethylamine, 2-(aminoethyl)morpholine, 2-aminoethyl-N,N-dibutylamine, 4-amino-N-butylpiperidine or 2-(aminoethyl)pyrrolidine;R: a hydrogen or an OCH.sub.3 substituent.These new derivatives may be employed in the preparation of medicinal products intended for use as an antipsychotic, psychostimulatory, anti-autistic or antidepressant agent, an agent for treating Parkinson's disease or an antihypertensive agent.Type: GrantFiled: October 23, 1992Date of Patent: March 12, 1996Assignee: Institut National de la Sante et de la Recherche MedicaleInventors: Didier Rognan, Andre Mann, Camille-Georges Wermuth, Marie-Pascale Martres, Bruno Giros, Pierre Sokoloff, Jean-Charles Schwartz, Jeanne-Marie LeComte, Fabrice Garrido